A US Food and Drug Administration official allegedly influenced the decision by the agency to terminate a contract for a data project with one supplier and hire, without competitive tendering, a firm for which her husband was a paid advisor. According to the Los Angeles Times newspaper, "the FDA's handling of the matter illustrates how a small but well-positioned contractor gained a foothold - and how conflict of interests restraints are only as strict as the officials who enforce them."
Mark Boster, who recommended the Virginia-based Platinum Solutions to his wife, has since been hired in an executive capacity by the firm. In November 2006, Platinum Solutions won an extension to its $4.0 million contract.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze